NCT03716245Completed
Clinical Significance of Supraclavicular Lymph Node Dissection for Breast Cancer
A Multicenter, Randomised, Open-label Prospective Clinical Trial to Evaluate the Clinical Significance of Supraclavicular Lymph Node Dissection for Breast Cancer Patients With Ipsilateral Supraclavicular Lymph Node Metastasis
Source: ClinicalTrials.gov · Last updated 23 Jan 2024
Brief summary (registry, in English)
Breast cancer patients with ipsilateral supraclavicular lymph node metastasis are defined as Ⅲc stage (N3) according to the newly published 8th AJCC TNM staging system. No concret guide line was supported to such patients. It is still pending whether to exert supraclavicular lymph node dissection to breast cancer patients with ipsilateral supraclavicular lymph node metastasis. To evaluate the clinical significance and complication of supraclavicular lymph node dissection for breast cancer patients with ipsilateral supraclavicular lymph node metastasis, the investigators randomize patients into two groups, one group is supraclavicular lymph node dissection with radiotherapy group, the other group is radiotherapy group.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 180 (actual)
- First submitted
- 14 Oct 2018
- Start date
- 27 Feb 2019
- Primary completion date
- 20 Jan 2024
- Lead sponsor
- Xinhong Wu, PhD
- Diseases
- Childhood cancers
- NCT number
- NCT03716245
What you commit to
- Study type: Interventional
- Participants enrolled: 180
- From 27 Feb 2019 to the primary completion date, 20 Jan 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Absolute and relative contraindication for surgery or radiation；
- existing distant metastasis before surgery；
- Previous history of breast cancer or other malignancies；
Other illness
- non-invasive breast cancer；
- with contralateral breast cancer；
- inflammatory breast cancer；
Other
- ECOG≥2；
- pregnancy；
- any serious complications which caused patients not suitable to participate this study
Who the study is looking for
- Ability to understand the study procedures and contents, and willingness to voluntarily sign the written informed consent form;
- Age≤75 years old, female;
- Histologically confirmed breast cancer;
- Histologically or cytologically confirmed ipsilateral supraclavicular lymph node metastasis；
- cT0-T3；
- low and moderate risk for anesthesia
Age in the registry: - to 75 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Wu Xinhong Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.